Viridian Intersects 15m of 1.1% CuEq in 1.5km Step-Out Drilling at Kraken MainGlobeNewsWire · 1 day ago
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026Business Wire · 4 days ago
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsDefense World · Sep 30, 2026
Viridian Therapeutics: Two Products, One Commercial BuildoutSeeking Alpha · Sep 17, 2026
Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken MainGlobeNewsWire · Sep 8, 2026
27,472 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Jupiter Topco LLCDefense World · Sep 8, 2026Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$1.03 | -$1.05 | Miss |
| May 5, 2026 | -$1.06 | -$0.90 | Beat |
| Feb 26, 2026 | -$0.90 | -$1.08 | Miss |
| Nov 5, 2025 | -$0.82 | -$0.34 | Beat |
| Aug 6, 2025 | -$1.00 | -$1.00 | Beat |
| May 6, 2025 | -$0.95 | -$0.87 | Beat |